Nikolaeva Natalia, Bemelman Frederike J, Yong Si-La, van Lier René A W, ten Berge Ineke J M
Department of Experimental Immunology, Academic Medical Centre, Amsterdam, the Netherlands.
Transplantation. 2006 Feb 15;81(3):445-54. doi: 10.1097/01.tp.0000194860.21533.b9.
Studies in mice have shown that rapamycin inhibits cell cycle progression and promotes the development of clonal anergy. We here addressed the question if rapamycin can induce anergy of human T cells and studied the effects of rapamycin on activation, proliferation and expression of cytotoxic effector molecules of alloresponsive T cells in mixed lymphocyte cultures.
Peripheral blood mononuclear cells from healthy individuals were labeled with CFSE to monitor subsequent cell divisions. Cells were cocultured with allogeneic irradiated cells in the presence or absence of rapamycin. Flowcytometric analysis was performed after staining for surface CD4, CD8, and CD25 and for intracellular perforin, granzyme B, active caspase-3, and TGF-beta. Bio-Plex cytokine assay was done to measure the secretion of IL-2, IL-4, IL-10, and IFN-gamma.
Addition of rapamycin at a final concentration of 10 ng/ml strongly decreased precursor frequencies of alloreactive CD4+ and CD8+ T cells. However, when these cells were washed and subsequently specifically restimulated in the absence of rapamycin, the proliferative capacity appeared normal. Next to lowering precursor frequencies, rapamycin also inhibited T cell expansion by inducing apoptosis in divided alloreactive CD4+ and CD8+ T cells. Rapamycin did not interfere with the formation of CD25brightCD4+ T cells during allogeneic stimulation and did not inhibit their suppressive function. Furthermore, the drug decreased production of effector molecules perforin and granzyme B by alloreactive T cells and diminished alloreactive cytotoxicity.
Our data show that rapamycin strongly inhibits proliferation and effector functions of alloreactive T cells in vitro, but does not induce alloantigen specific nonresponsiveness.
对小鼠的研究表明,雷帕霉素可抑制细胞周期进程并促进克隆无能的发展。我们在此探讨雷帕霉素是否能诱导人T细胞无能,并研究雷帕霉素对混合淋巴细胞培养中同种异体反应性T细胞的活化、增殖及细胞毒性效应分子表达的影响。
用羧基荧光素二醋酸盐琥珀酰亚胺酯(CFSE)标记健康个体的外周血单个核细胞,以监测后续细胞分裂。细胞在有或无雷帕霉素的情况下与异体辐照细胞共培养。对表面CD4、CD8和CD25以及细胞内穿孔素、颗粒酶B、活性半胱天冬酶-3和转化生长因子-β进行染色后,进行流式细胞术分析。采用生物芯片细胞因子检测法测定白细胞介素-2(IL-2)、IL-4、IL-10和γ干扰素(IFN-γ)的分泌情况。
加入终浓度为10 ng/ml的雷帕霉素可显著降低同种异体反应性CD4+和CD8+T细胞的前体细胞频率。然而,当这些细胞被洗涤并随后在无雷帕霉素的情况下进行特异性再刺激时,其增殖能力似乎正常。除了降低前体细胞频率外,雷帕霉素还通过诱导分裂的同种异体反应性CD4+和CD8+T细胞凋亡来抑制T细胞扩增。雷帕霉素在同种异体刺激过程中不干扰CD25brightCD4+T细胞的形成,也不抑制其抑制功能。此外,该药物可降低同种异体反应性T细胞效应分子穿孔素和颗粒酶B的产生,并减弱同种异体反应性细胞毒性。
我们的数据表明,雷帕霉素在体外可强烈抑制同种异体反应性T细胞的增殖和效应功能,但不会诱导同种异体抗原特异性无反应性。